Galmed Pharmaceuticals (GLMD) Stock
Small biotech developing treatments for liver diseases. Here's the price, business snapshot, and what's worth knowing about Galmed Pharmaceuticals in August 2026.
Galmed Pharmaceuticals Ltd (GLMD) is a small-cap, clinical-stage biopharmaceutical company focused on developing treatments for metabolic and liver diseases, notably non-alcoholic steatohepatitis (NASH). With a market capitalisation of about $7.84 million, Galmed sits in the higher-risk segment of the market: progress depends heavily on clinical trial outcomes, regulatory decisions and the company’s ability to secure funding or partnerships. Investors should be aware that small biotechs can experience large price swings and potential dilution if additional capital is needed. Key things to watch are trial readouts, licensing deals, cash runway and management updates. This summary is educational and not personalised financial advice; whether this stock is suitable depends on your goals, timeframe and risk tolerance. Past events or promising science do not guarantee future returns, and investors should seek independent advice before making decisions.
About This Stock
GALMED PHARMACEUTICALS LTD
GLMD
Current Price
$4.80
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
GLMD
Market Cap
$4.97M
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Galmed Pharmaceuticals' stock with a target price of $12, indicating significant growth potential.
Financial Health
Galmed Pharmaceuticals is managing its finances reasonably well, but there are areas for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage focus
Progress hinges on trial results and regulatory review; positive readouts can be catalysts, though outcomes are uncertain.
Niche liver therapies
The company targets NASH and related metabolic liver conditions, a developing therapeutic area with unmet need and scientific complexity.
Volatile, high-risk stock
Small market cap means share prices can swing and funding needs may lead to dilution; suitable only for investors comfortable with speculative risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.